Test Price
2,400 AED✅ Home Collection Available
Lung Cancer Panel 1 (EGFR & ALK1) in UAE | AED 2400 | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Secure Medical Courier Solid Tissue Specimen Retrieval.
Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
This molecular panel detects activating EGFR mutations and ALK rearrangements in tumor tissue (FFPE or fresh biopsy) using Sanger sequencing and FISH, enabling targeted therapy selection for non‑small cell lung cancer. Rapid 5–7 day turnaround with ISO‑certified quality assurance.
Test Overview & Methodology
The Lung Cancer Panel 1 (EGFR & ALK1) is a molecular genetic test detecting activating mutations in the EGFR gene and rearrangements in the ALK gene via Sanger sequencing and fluorescence in‑situ hybridization (FISH) on tumor tissue. This panel is critical for guiding targeted therapy (EGFR tyrosine kinase inhibitors and ALK inhibitors) in non‑small cell lung cancer, with a rapid 5–7 day turnaround.
| Feature | Our Test (Lung Cancer Panel 1) | Closest Alternative |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity (Sanger + FISH) | NGS panels with lower mutation‑specific sensitivity |
| Methodology | Sanger Sequencing & FISH (Gold Standard for EGFR/ALK) | Next‑Generation Sequencing (NGS) with broader but less focused coverage |
| Speed | 5–7 Days | 10–14 Days for comprehensive NGS |
Physician Insight & Safety Protocols
“As a physician, I emphasize that while this test offers high precision for EGFR and ALK alterations, results must always be correlated with clinical context and histopathological findings. A positive result may open the door to life‑changing targeted therapies, but a negative result does not exclude all driver mutations.”
— Mr. Prabhakar Reddy Kalathoor, DHA Registration ID: 61713011
Advisory Note
Do not discontinue prescribed medication without consulting your doctor. This test does not replace comprehensive oncological evaluation.
Exclusion Criteria & Emergency Red Flags
- If you are experiencing acute respiratory distress, severe hemoptysis, or sudden neurological changes, seek emergency care immediately – do not wait for test results.
- This test is not suitable as a standalone screening for individuals without a confirmed tissue diagnosis of lung cancer; a biopsy must be performed first.
- Patients with known severe coagulation disorders may require special sample handling; notify our team before collection.
- Pregnant patients: the test can be performed with a doctor’s prescription modifier, but clinical urgency must be assessed by your oncologist.
Patient FAQ & Clinical Guidance
1. What does the Lung Cancer Panel 1 (EGFR & ALK1) test detect, and who needs it?
This molecular test identifies EGFR mutations and ALK gene rearrangements in tumor tissue, essential for selecting targeted therapy in non‑small cell lung cancer patients.
2. How should I prepare for the sample collection?
No special preparation is required. The sample is an archival tissue specimen (FFPE block or fresh biopsy) already obtained during a hospital procedure. Our secure medical courier retrieves the solid tissue specimen from the accredited facility.
3. How long do results take, and will a doctor explain them to me?
Results are delivered within 5–7 business days and include a telephonic post‑test clinical guidance session with an expert to interpret the findings and discuss next steps.
4. Do I need a doctor's prescription to take this test?
Yes, a doctor’s prescription is required as this is a specialized molecular oncology test. Exceptions may apply for surgical oncology cases or confirmed pregnancy with specialist clearance.
UAE Regulatory & Data Privacy Adherence
This test fully adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient data is protected under strict medical confidentiality standards. DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | Lung Cancer Panel 1 (EGFR & ALK1) |
| Price (AED) | 2,400 |
| Turnaround Time | 5–7 Business Days |
| Sample Type / Matrix | Tumor Tissue (FFPE Block or Fresh Biopsy) |
| Methodology Used | Sanger Sequencing & Fluorescence In‑Situ Hybridization (FISH) |
| ICD-10-CM Code | C34.9 |
| LOINC Code | 21604-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians